Table 2.
Prevalence of infections and antifungal treatments
| Prevalence or duration | ||
|---|---|---|
| Prevalence of infections | ||
| CAPA*: pr/pb invasive aspergillosis | 76 (15%) | |
| pr/pb invasive fungal infection other than pr/pb CAPA (one or more) | 38 (7%) | |
| Candidemia | 32 (6%) | |
| Invasive mucormycosis | 6 (1%) | |
| Invasive fusariosis | 1 (<1%) | |
| Bacterial ventilator-associated pneumonia (n=509)† | 374 (73%) | |
| Cytomegalovirus infection (n=491)† | 49 (10%) | |
| Herpes simplex virus type 1 infection (n=491)† | 76 (15%) | |
| Duration of antifungal treatment, days | ||
| Fluconazole (n=30)‡ | 19·2 (20·4) | |
| Caspofungin (n=70)‡ | 7·9 (9·1) | |
| Liposomal amphotericin B (n=34)‡ | 11·8 (27·5) | |
| Voriconazole (n=73)‡ | 15·2 (16·1) | |
| Isavuconazole (n=15)‡ | 12·3 (6·1) | |
Data are n (%) or mean (SD). CAPA=COVID-19-associated pulmonary aspergillosis. pr/pb=proven or probable.
CAPA status according to Koehler et al;8 in addition, 24 (5%) of 509 patients with a compatible clinical context were positive for Aspergillus spp in non-bronchoalveolar lavage or bronchial or tracheal aspiration but did not meet the criteria for pr/pb CAPA; these were classified as possible IFIs. Some patients with pr/pb CAPA or possible CAPA also had other IFIs, thus 128 patients with pr/pb or possible IFIs had 138 episodes overall.
Number of patients with available data.
Number of patients receiving each treatment; denominator for each group (ie, patients with available data on antifungal treatments) was 162.